SCHEMBL7253545

SCHEMBL7253545

CC(NC1CC1)c1cc2ccc(Br)cc2[nH]1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
AHR P35869 1/20 0.37
CYP2D6 P10635 2/20 0.35
KCNH2 Q12809 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ITK Q08881 1/20 0.33
RET P07949 1/20 0.32
NOS1 P29475 1/20 0.32
METAP2 P50579 1/20 0.32
DYRK1A Q13627 1/20 0.32
PARP1 P09874 2/20 0.32
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7253280 0.76 HTR1D (0.36)
SCHEMBL22529412 0.73 LMNA (0.41) DRD4HRH4AHRLMNARAB9A
SCHEMBL7253533 0.72 SLC6A2 (0.40) DRD4HRH4AHRLMNARAB9A
SCHEMBL20614433 0.70 AHR (0.42) HRH4AHRLMNARAB9AITK
SCHEMBL23458903 0.69 AHR (0.39) DRD4HRH4AHRLMNARAB9A
SCHEMBL29919166 0.69 AHR (0.39) DRD4HRH4AHRLMNARAB9A
SCHEMBL22529399 0.69 PARP1 (0.38) HRH4CYP2D6KCNH2LMNADYRK1A
SCHEMBL22529441 0.68 CYP19A1 (0.42) HRH4AHRLMNARAB9ANOS1
SCHEMBL16944175 0.68 GAA (0.56) LMNAGAAL3MBTL1ALDH1A1
SCHEMBL20534668 0.66 DRD4 (0.58) DRD4HRH4RAB9ARET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6635639-B2 Treatment or diagnosis of central nervous system conditions NPS ALLELIX CORP. (CA) 2003-10-21 US disclosed
US-20020169322-A1 Use of N-alkylamino-heterocylic compounds for the treatment of migraine NPS ALLEXLIX CORP. 2002-11-14 US disclosed
US-6380242-B1 FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS NPS ALLELIX CORP. (CA) 2002-04-30 US disclosed
EP-1140074-A1 INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE NPS Allelix Corp. (CA) 2001-10-10 EP disclosed
WO-2000038677-A1 INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE ALLELIX BIOPHARMACEUTICALS INC. (CA) 2000-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169322-A1 Use of N-alkylamino-heterocylic compounds for the treatment of migraine CNR1, CNR2, KCNH1 DRD4 1639/4885HRH4 31/4885AHR 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.